CLINICAL_TRIALS
trial_result
· 2011-10-20
Clinical Trial Update: SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 2]
Summary
A Phase 2 study evaluating SU5416 in combination with interferon alfa-2b for unresectable or metastatic renal cell carcinoma has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: City of Hope Medical Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED